- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2021-03
2035-03
2035-03
200
NCT04707365
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
INTERVENTIONAL
Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort
Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved. In addition, strategies for the therapeutic management of these cancers are evolving in the context of the development of immunotherapies. Tumor microenvironment is a potential source of new diagnostic, prognostic and predictive markers and new therapeutic targets. The links between tumor microenvironment and modulation of the immune system in colorectal and pancreatobiliary cancers are poorly understood. Molecular classifications have been proposed for these cancers, but their link with immunity and response to treatment remains to be explored. Objective : explore links between molecular subtypes, tumor microenvironment, host (immune system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic value), response (predictive value) and tolerance (toxicities) to treatments in digestive cancers, in particular colorectal and pancreatobiliary cancers. Method: Retrospective and prospective monocentric cohort study
N/A
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2021-01-12 | N/A | 2021-01-12 |
2021-01-12 | N/A | 2021-01-13 |
2021-01-13 | N/A | 2020-12 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
Prevention
Allocation:
Na
Interventional Model:
Single Group
Masking:
None
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| EXPERIMENTAL: digestive cancers Colorectal and pancreatobiliary cancers | BIOLOGICAL: Tumor samples
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| overall survival | Overall survival (OS): vital status (alive/deceased) | observation from first cancer treatment date until date of death or 10 years follow up if patient alive |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: Christophe Tournigand, MD-PHD Phone Number: 0149812567 Email: christophe.tournigand@aphp.fr |
Study Contact Backup Name: Ilaria Cascone, PHD Phone Number: 0149813765 Email: ilaria.cascone@u-pec.fr |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.
The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.
